Eloxx Pharmaceuticals, Inc. (ELOX)
OTCMKTS · Delayed Price · Currency is USD
0.120
0.00 (0.00%)
At close: Apr 29, 2026

Eloxx Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Revenue
-6.36---
Upgrade
Gross Profit
-6.36---
Upgrade
Selling, General & Admin
3.385.258.6911.3920.55
Upgrade
Research & Development
3.063.588.623.0321.8
Upgrade
Operating Expenses
6.448.8317.2934.4242.35
Upgrade
Operating Income
-6.44-2.47-17.29-34.42-42.35
Upgrade
Interest Expense
-1.05-1.14-1.15-1.95-1.26
Upgrade
Interest & Investment Income
0.030.030.250.270.01
Upgrade
Currency Exchange Gain (Loss)
----00
Upgrade
Other Non Operating Income (Expenses)
0.070.431.280.03-
Upgrade
EBT Excluding Unusual Items
-7.39-3.16-16.91-36.07-43.6
Upgrade
Merger & Restructuring Charges
-----1
Upgrade
Gain (Loss) on Sale of Assets
00.040.29--
Upgrade
Other Unusual Items
1.39-0.03-0.44-0.54
Upgrade
Pretax Income
-6-3.14-17.05-36.07-66.73
Upgrade
Net Income
-6-3.14-17.05-36.07-66.73
Upgrade
Net Income to Common
-6-3.14-17.05-36.07-66.73
Upgrade
Shares Outstanding (Basic)
124322
Upgrade
Shares Outstanding (Diluted)
124322
Upgrade
Shares Change (YoY)
228.49%46.22%18.66%23.86%74.36%
Upgrade
EPS (Basic)
-0.49-0.84-6.63-16.65-38.15
Upgrade
EPS (Diluted)
-0.49-0.84-6.63-16.65-38.15
Upgrade
Free Cash Flow
-6.33-4.72-14.34-31.91-35.09
Upgrade
Free Cash Flow Per Share
-0.51-1.25-5.58-14.73-20.06
Upgrade
Gross Margin
-100.00%---
Upgrade
Operating Margin
--38.81%---
Upgrade
Profit Margin
--49.43%---
Upgrade
Free Cash Flow Margin
--74.15%---
Upgrade
EBITDA
-6.4-2.43-17.18-34.34-42.23
Upgrade
EBITDA Margin
--38.26%---
Upgrade
D&A For EBITDA
0.040.040.110.080.11
Upgrade
EBIT
-6.44-2.47-17.29-34.42-42.35
Upgrade
EBIT Margin
--38.81%---
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.